Tanai Therapeutics, based in Belgium, is developing a differentiated small molecule approach for obesity and cardiometabolic disease by targeting energy expenditure pathways
Tanai Therapeutics, based in Belgium, is developing a differentiated small molecule approach for obesity and cardiometabolic disease by targeting energy expenditure pathways. The Company’s strategy is guided by human genetics and translational biology, with the aim of developing therapies that may complement existing appetite-modulating treatments or provide orthogonal stand-alone approaches for patients with obesity and related metabolic diseases.